Extended Data Fig. 3. Elevated baseline pIL8 is associated with poor clinical outcome.

a, Kaplan-Meier curves depict overall survival (OS) of median T-effector (Teff) signature in cohort 2 of IMvigor210. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated using stratified Cox proportional hazards regression models, and p values were calculated using stratified log-rank test. HR and p value are adjusted for age, sex, race, ECOG performance status, presence of liver metastasis, and tumor burden (sum of longest diameter, SLD). b, Kaplan-Meier curves depict overall survival (OS) of baseline plasma IL8 (pIL8) levels in cohort 1 of IMvigor210. Censored data are indicated by vertical tick marks in Kaplan-Meier curves. Number of patients per group and time point are indicated below the graphs. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated using stratified Cox proportional hazards regression models, and p values were calculated using stratified log-rank test. HR and p value are adjusted for age, sex, race, ECOG performance status, presence of liver metastasis, and tumor burden (sum of longest diameter, SLD). c, Association between high vs low pIL8 (median cutoff) and Objective Response Rate (ORR) in cohort 1 of IMvigor210. High baseline pIL8 levels were associated with a higher number of nonresponders (SD and PD) (P= 0.025, two-sided Fisher’s exact test) by Response Evaluation Criteria in Solid Tumors (RECIST) 2.1. [CR: complete response; PR, partial response; SD, stable disease; PD, progressive disease]. d, Association between high vs low Teff (median cutoff) and OS in cohort 2 of IMvigor210 (HR: 0.71, 95% CI: 0.53, 0.95, P=0.0201). Hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated using stratified Cox proportional hazards regression models, and p values were calculated using stratified log-rank test. HR and p value are adjusted for sex, age, race, ECOG performance status, presence of liver metastasis, and tumor burden (sum of longest diameter, SLD). e, Association between high vs low baseline plasma IL8 (median cutoff) and Objective Response Rate (ORR) in IMmotion150A trend in low plasma IL8 in Atezo monotherapy associated with a higher number of responders compared to Atezo+Bev and Sunitinib treatment arms (CR and PR) (P= 0.348, 0.409 and 0.271, respectively two-sided Fisher’s exact test) f, Association of high vs low of baseline tumor IL8 expression and Objective Response Rate (ORR) in IMmotion150. A trend observed in low tumor IL8 in atezo monotherapy associated with higher numbers of responders (CR and PR) compared to Atezo+Bev and Sunitinib treatment arms (P= 0.178, 0.05, and 0.773, respectively).